Clinical Trials Logo

Advanced Solid Tumor clinical trials

View clinical trials related to Advanced Solid Tumor.

Filter by:

NCT ID: NCT06260774 Not yet recruiting - Clinical trials for Advanced Solid Tumor

Study of TTX-MC138 in Subjects With Advanced Solid Tumors

Start date: July 1, 2024
Phase: Phase 1/Phase 2
Study type: Interventional

A Phase 1/2 Multicenter, Open-Label, Dose-Escalation and Expansion Study of TTX MC138 in Subjects with Advanced Solid Tumors

NCT ID: NCT06257680 Not yet recruiting - Clinical trials for Advanced Solid Tumor

A Phase I Study on ReT01 ACT for the Treatment of Advanced Solid Tumors

Start date: February 18, 2024
Phase: Phase 1
Study type: Interventional

This single-armed, open, phase I study was designed to evaluate the safety and tolerance of ReT01 ACT injection in the treatment of advanced solid tumors. The phase I clinical trial is expected to be finished in 1 year.

NCT ID: NCT06147037 Not yet recruiting - Clinical trials for Non-small Cell Lung Cancer

A Phase 1, Dose-escalation Study of [225Ac]-FPI-2068 in Adult Patients With Advanced Solid Tumours

Start date: June 28, 2024
Phase: Phase 1
Study type: Interventional

This is a first-in-human, Phase 1, non-randomized, multicenter, open-label clinical study designed to investigate the safety, tolerability, dosimetry, biodistribution, and pharmacokinetics (PK) of [225Ac]-FPI-2068, [111In]-FPI-2107, and FPI-2053 in metastatic and/or recurrent solid tumors (HNSCC, NSCLC, mCRC, PDAC).

NCT ID: NCT06144723 Not yet recruiting - Clinical trials for Advanced Solid Tumor

Study of HS-20105 for Injection in Patients With Advanced Solid Tumors.

Start date: March 1, 2024
Phase: Phase 1/Phase 2
Study type: Interventional

HS-20105 is a novel antibody-drug conjugate (ADC) targeting Trop-2. This first-in-human trial is aimed to assess the maximum tolerated dose (MTD) and dose limiting toxicity (DLT), to evaluate the pharmacokinetics (PK), safety and preliminary anti-tumor activity of HS-20105 in patients with advanced solid tumors.

NCT ID: NCT06139211 Not yet recruiting - Clinical trials for Advanced Solid Tumor

A Phase Ib/II Study Of JS015 Combination Therapy in Advanced Solid Tumors

Start date: November 30, 2023
Phase: Phase 1/Phase 2
Study type: Interventional

This is a phase Ib/II, open-label, multicenter study to evaluate the safety, tolerability, pharmacokinetics (PK), and preliminary efficacy of JS015 combination therapy in patients with advanced solid tumors. The Recommended dose for phase II trial (RP2D) will be determined based on the safety, tolerability, pharmacokinetics and efficacy.

NCT ID: NCT06132217 Not yet recruiting - Clinical trials for Advanced Solid Tumor

A Study of Simmitinib Plus SG001 in Advanced Solid Tumors

Start date: January 30, 2024
Phase: Phase 1/Phase 2
Study type: Interventional

This is an open-label Phase I/II trial of simmitinib plus SG001 in patients with advanced solid tumors. Phase I will determine and confirm the maximum tolerated dose (MTD) and recommended phase II dose (RP2D) for simmitinib in combination with SG001 in patients with advanced solid tumors. Phase 2 (Expansion) will evaluate the safety and efficacy of the combination in 3 cohorts at the RP2D from Phase I.

NCT ID: NCT06084286 Not yet recruiting - Clinical trials for Advanced Solid Tumor

Dual-targeting CLDN18.2 and PD-L1 CAR-T for Patients With CLDN18.2-positive Advanced Solid Tumors

Start date: October 30, 2023
Phase: Phase 1
Study type: Interventional

Claudin18.2(CLDN18.2) is a kind of integrin membrane protein in the tight junction between epithelium and endothelium, which is highly expressed in many solid tumors, especially in gastric cancer and pancreatic cancer. The CLDN18.2/PD-L1 dual-targeting CAR-T will be investigated in patients with CLDN18.2-positive advance solid tumors.

NCT ID: NCT06078670 Not yet recruiting - Clinical trials for Advanced Solid Tumor

PARP Inhibitor CVL218 in Combination Therapy for Patients With Advanced Solid Tumors

Start date: October 10, 2023
Phase: Phase 1/Phase 2
Study type: Interventional

This study aims to evaluate the efficacy of CVL218 in combination with Toripalimab injection/Sintilimab injection (Darbersol, Sintilimab) in the treatment of advanced solid tumors. It focuses on assessing the safety, tolerability, and pharmacokinetic profile of a three-drug combination regimen comprising albumin-bound paclitaxel injection (Kealil), paclitaxel injection (Taxol), and Fuquinitinib capsule (Aiutec, Fruquintinib).

NCT ID: NCT05983523 Not yet recruiting - Clinical trials for Advanced Solid Tumor

A Study of PEP07 (Checkpoint Kinase 1 Inhibitor) in Patients With Advanced or Metastatic Solid Tumors

Start date: December 28, 2023
Phase: Phase 1
Study type: Interventional

The goal of this clinical trial is To establish the safety profile and determine the dose-limited toxicity (DLT) of PEP07 monotherapy in patients with advanced or metastatic solid tumors. To determine the maximum tolerated dose (MTD) and/or recommended Phase 2 dose (RP2D) of PEP07 monotherapy. Participants will receive PEP07 administered orally once daily (QD) for 2 consecutive days and 5 days off, every week for 4 weeks until disease progression, intolerable toxicity, confirmed pregnancy, death, consent withdrawal, or other anti-cancer treatment is required, or the Sponsor ends the study, whichever occurs first.

NCT ID: NCT05979155 Not yet recruiting - Clinical trials for Advanced Solid Tumor

A Study of NWY001 in Subjects With Advanced Solid Tumors

Start date: October 2023
Phase: Phase 1
Study type: Interventional

This is a Phase 1, single-arm, open-label, dose-escalation study in patients with advanced solid tumors including 2 parts: Part 1: Dose-Escalation Part Part 2: Dose-Expansion Part